GGrantIndex
← Search

Protocol Review and Monitoring

$356,865P30FY2012CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications, trials & patents

Trial NCT07407920Trial NCT07349641Trial NCT06651580Trial NCT05681026Trial NCT05223036Trial NCT05078866Trial NCT05057312Trial NCT05054296Trial NCT05044546Trial NCT05023967Trial NCT05011045Trial NCT04875728Trial NCT04870645Trial NCT04810091Trial NCT04751422Trial NCT04740164Trial NCT04668300Trial NCT04615013Trial NCT04505267Trial NCT04484909Trial NCT04483349Trial NCT04481204Trial NCT04474301Trial NCT04458610Trial NCT04447222Trial NCT04435691Trial NCT04430725Trial NCT04407247Trial NCT04373720Trial NCT04317781Trial NCT04311723Trial NCT04310826Trial NCT04310397Trial NCT04265430Trial NCT04257045Trial NCT04256941Trial NCT04239989Trial NCT04239976Trial NCT04239157Trial NCT04236882Trial NCT04228042Trial NCT04220827Trial NCT04220775Trial NCT04220008Trial NCT04219969Trial NCT04219904Trial NCT04216732Trial NCT04216563Trial NCT04216524Trial NCT04216472Trial NCT04215029Trial NCT04200534Trial NCT04199026Trial NCT04196972Trial NCT04189783Trial NCT04189770Trial NCT04189757Trial NCT04188418Trial NCT04188405Trial NCT04186884Trial NCT04186832Trial NCT04185337Trial NCT04181463Trial NCT04171622Trial NCT04171219Trial NCT04171037Trial NCT04169763Trial NCT04169737Trial NCT04169542Trial NCT04160052Trial NCT04151082Trial NCT04150939Trial NCT04140487Trial NCT04135326Trial NCT04134208Trial NCT04132843Trial NCT04132505Trial NCT04132440Trial NCT04129138Trial NCT04128748Trial NCT04128501Trial NCT04127721Trial NCT04125914Trial NCT04119037Trial NCT04106843Trial NCT04106245Trial NCT04090619Trial NCT04090567Trial NCT04087057Trial NCT04083378Trial NCT04082572Trial NCT04074746Trial NCT04066894Trial NCT04062305Trial NCT04062266Trial NCT04058964Trial NCT04054245Trial NCT04054167Trial NCT04054154Trial NCT04053517

Abstract

The primary goal of the Protocol Review and Monitoring System (PRMS) is to ensure that all human subjects research is of the highest scientific quality. This resource is available to over 1300 faculty members. Over the past 5 years, on average annual 542 faculty members utilized the PRMS and participated in human subjects research each year. PRMS is supported by 29 staff members under the direction of Dr. Maurie Markman, Vice President for Clinical Research. The core function of the PRMS is to provide a mechanism to assure adequate internal oversight of the scientific and research aspects of all institutional clinical trials. The focus is to review the scientific merit, progress, and priorities of the clinical research protocols conducted by the faculty. This function is coordinated by PRMS as a single source of service, support and oversight. The PRMS is made of up several subcommittees that are designated to provide scientific review and approval for new research protocols, as well as monitor the progress of the protocols. During the last five years, new services provided include a function that allows Regulatory Specialists to review new submissions for format and completeness of information and either reject or accept the submissions electronically. This includes the use of a specialized electronic information sheet (a resubmission memo) that lists amendments made prior to resubmitting the revised protocol document. This is a valuable tool that is also used during the review process when a protocol is initially submitted. The electronic review document provided by each assigned reviewer during the scientific review process can be compared to this resubmission memo to ensure all items of concern have been addressed by the investigator. Additionally, the electronic protocol eligibility, abstract, and informed consent documents for all trials that have been submitted through the PDOL are made available on an intranet web page that is accessible by the patient care units. The navigational web page provides protocol status information as well, including when a protocol has been closed to new subject accrual. This allows caregivers to have ready access to current protocol information from time of activation, during new subject accrual and treatment though completion of the protocol. This information is provided in real time and no delays occur after regulatory approval of the protocol. During the last fiscal year, the funds used to support the PRMS function were $246,418 (15%) from the Cancer Center Support Grant (CCSG), $172,163 (10%) from user fees, and $1,259,771 (75%) from the institution. It is projected that in the next award cycle, the increase in support provided by the CCSG will alter the sources of funds such that the percentages provided by the CCSG ($258,228), the user fees ($286,937) and the institution ($1,526,868), will be 12%, 14% and 74%, respectively. The PRMS supported 2739 protocols from 599 cancer center members, of which 81% hold peer-reviewed funding. During the last several years, the number of new protocols managed by PRMS has remained constant. Protocols that do not meet the UTMDACC scientific standards are typically withdrawn from submission and review. While the volume of protocols has not increased, the activity involved in oversight has become increasingly more detailed due to the evolution of regulatory requirements.

View original record on NIH RePORTER →